"At Yale New Haven Health, we deliver extraordinary, compassionate care by working alongside providers and payers on innovative, cost-effective healthcare delivery models that improve care and value for patients - and enhance the health of our communities."

During the past decade, c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator and "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven" are "CD33 Positive Acute Myelogenous Leukemia" (1 trials), "Cancer of the Prostate" (1 trials), "Nonmetastatic Castration-Resistant Prostate Cancer" (1 trials), "Ovarian Cancer" (1 trials) and "Prostate Cancer" (1 trials). Many other conditions were trialed in "c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven" in a lesser frequency.

Most popular intervention types in "c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Antibody Drug Conjugate Chemotherapeutic" (1 trials), "Avelumab" (1 trials), "Enzalutamide" (1 trials), "Placebo" (1 trials) and "carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven" are 1 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".